Critical concepts in adaptive clinical trials

被引:63
作者
Park, Jay J. H. [1 ]
Thorlund, Kristian [2 ,3 ]
Mills, Edward J. [2 ,3 ]
机构
[1] Univ British Columbia, Dept Med, Vancouver, BC, Canada
[2] McMaster Univ, Dept Hlth Res Methods Evidence & Impact HEI, 1280 Main St W, Hamilton, ON L8S 4L8, Canada
[3] Bill & Melinda Gates Fdn, Seattle, WA USA
来源
CLINICAL EPIDEMIOLOGY | 2018年 / 10卷
关键词
adaptive designs; response adaptive randomization; sample size reassessment; Bayesian adaptive trials; seamless trials; adaptive enrichment; MIXED-METHODS ANALYSIS; ENRICHMENT DESIGNS; BREAST-CANCER; DOSE-RESPONSE; ACUTE STROKE; RANDOMIZATION; PERSPECTIVES; THERAPY; FAILURE; ASTIN;
D O I
10.2147/CLEP.S156708
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Adaptive clinical trials are an innovative trial design aimed at reducing resources, decreasing time to completion and number of patients exposed to inferior interventions, and improving the likelihood of detecting treatment effects. The last decade has seen an increasing use of adaptive designs, particularly in drug development. They frequently differ importantly from conventional clinical trials as they allow modifications to key trial design components during the trial, as data is being collected, using preplanned decision rules. Adaptive designs have increased likelihood of complexity and also potential bias, so it is important to understand the common types of adaptive designs. Many clinicians and investigators may be unfamiliar with the design considerations for adaptive designs. Given their complexities, adaptive trials require an understanding of design features and sources of bias. Herein, we introduce some common adaptive design elements and biases and specifically address response adaptive randomization, sample size reassessment, Bayesian methods for adaptive trials, seamless trials, and adaptive enrichment using real examples.
引用
收藏
页码:343 / 351
页数:9
相关论文
共 25 条
[1]   Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review [J].
Antoniou, Miranta ;
Jorgensen, Andrea L. ;
Kolamunnage-Dona, Ruwanthi .
PLOS ONE, 2016, 11 (02)
[2]  
BARTLETT RH, 1985, PEDIATRICS, V76, P479
[3]   The reassessment of trial perspectives from interim data - a critical view [J].
Bauer, P ;
Koenig, F .
STATISTICS IN MEDICINE, 2006, 25 (01) :23-36
[4]   Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls [J].
Bauer, Peter ;
Bretz, Frank ;
Dragalin, Vladimir ;
Koenig, Franz ;
Wassmer, Gernot .
STATISTICS IN MEDICINE, 2016, 35 (03) :325-347
[5]  
Bolstad W.M., 2016, Introduction to Bayesian statistics
[6]   Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas [J].
Casali, Paolo G. ;
Le Cesne, Axel ;
Velasco, Andres Poveda ;
Kotasek, Dusan ;
Rutkowski, Piotr ;
Hohenberger, Peter ;
Fumagalli, Elena ;
Judson, Ian R. ;
Italiano, Antoine ;
Gelderblom, Hans ;
Adenis, Antoine ;
Hartmann, Jorg T. ;
Duffaud, Florence ;
Goldstein, David ;
Broto, Javier M. ;
Gronchi, Alessandro ;
Dei Tos, Angelo P. ;
Marreaud, Sandrine ;
van der Graaf, Winette T.A. ;
Zalcberg, John R. ;
Litiere, Saskia ;
Blay, Jean-Yves .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (36) :4276-4283
[7]   A seamless Phase IIB/III adaptive outcome trial: Design rationale and implementation challenges [J].
Chen, Y. H. Joshua ;
Gesser, Richard ;
Luxembourg, Alain .
CLINICAL TRIALS, 2015, 12 (01) :84-90
[8]  
CHMP (Committee for Medicinal Products for Human Use), 2006, REFL PAP METH ISS CO
[9]   When is a seamless study desirable? Case studies from different pharmaceutical sponsors [J].
Cuffe, Robert L. ;
Lawrence, David ;
Stone, Andrew ;
Vandemeulebroecke, Marc .
PHARMACEUTICAL STATISTICS, 2014, 13 (04) :229-237
[10]   ASTIN: a Bayesian adaptive dose-response trial in acute stroke [J].
Grieve, AP ;
Krams, M .
CLINICAL TRIALS, 2005, 2 (04) :340-351